Nile Pharmaceuticals and Chemical Industries Company (EGX:NIPH)
Egypt · Delayed Price · Currency is EGP 266.51
-2.49 (-0.93%)
At close: Oct 22, 2026
EGX:NIPH Income Statement
Financials in millions EGP. Fiscal year is July - June.
Millions EGP. Fiscal year is Jul - Jun.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
| 2,134 | 1,290 | 1,143 | 1,005 | 876.78 | |
Revenue Growth | 65.48% | 12.86% | 13.66% | 14.65% | 16.05% |
Cost of Revenue | 1,458 | 881.75 | 890.14 | 733.17 | 654.21 |
Gross Profit | 676.1 | 407.83 | 252.44 | 272.05 | 222.57 |
Selling, General & Admin | 140.47 | 114.48 | 101.98 | 100.02 | 91.51 |
Other Operating Expenses | 0.44 | 61.56 | 6.94 | 9.27 | 5.63 |
Operating Expenses | 140.91 | 176.03 | 108.93 | 109.28 | 97.13 |
Operating Income | 535.19 | 231.79 | 143.52 | 162.76 | 125.44 |
Interest Expense | -222.4 | -70.21 | -25.32 | -13.72 | -3.18 |
Interest & Investment Income | 6.17 | 6.41 | 2.05 | 2.25 | 4.79 |
Currency Exchange Gain (Loss) | 0.84 | 4.72 | 9.76 | 7.88 | - |
Other Non Operating Income (Expenses) | -5.4 | -2.31 | -21.77 | -14.04 | -10.76 |
EBT Excluding Unusual Items | 314.39 | 170.41 | 108.24 | 145.13 | 116.3 |
Gain (Loss) on Sale of Assets | 0.42 | - | - | 0.31 | - |
Legal Settlements | -2.45 | -7.18 | - | - | - |
Pretax Income | 312.36 | 163.23 | 108.24 | 145.44 | 116.3 |
Income Tax Expense | 55.99 | 37.5 | 18.01 | 26.22 | 26.63 |
Earnings From Continuing Operations | 256.37 | 125.73 | 90.23 | 119.21 | 89.67 |
Net Income | 256.37 | 125.73 | 90.23 | 119.21 | 89.67 |
Net Income to Common | 256.37 | 125.73 | 90.23 | 119.21 | 89.67 |
Net Income Growth | 103.91% | 39.35% | -24.32% | 32.94% | 39.20% |
Shares Outstanding (Basic) | 50 | 30 | 10 | 10 | 10 |
Shares Outstanding (Diluted) | 50 | 30 | 10 | 10 | 10 |
Shares Change | 66.67% | 196.30% | - | - | - |
EPS (Basic) | 5.13 | 4.19 | 8.91 | 11.77 | 8.86 |
EPS (Diluted) | 5.13 | 4.19 | 8.91 | 11.77 | 8.86 |
EPS Growth | 22.35% | -52.97% | -24.32% | 32.94% | 39.20% |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Free Cash Flow | -551.37 | -472.96 | -155.57 | -284.07 | -43.83 |
Free Cash Flow Per Share | -11.03 | -15.77 | -15.37 | -28.06 | -4.33 |
Dividend Per Share | - | 2.000 | 3.710 | 5.000 | 2.970 |
Dividend Growth | - | -46.09% | -25.80% | 68.35% | 48.50% |
Gross Margin | 31.68% | 31.62% | 22.09% | 27.06% | 25.39% |
Operating Margin | 25.08% | 17.97% | 12.56% | 16.19% | 14.31% |
Profit Margin | 12.01% | 9.75% | 7.90% | 11.86% | 10.23% |
Free Cash Flow Margin | -25.84% | -36.68% | -13.62% | -28.26% | -5.00% |
EBITDA | 602.03 | 260.37 | 155.52 | 492.94 | 139.36 |
EBITDA Margin | 28.21% | 20.19% | 13.61% | 49.04% | 15.89% |
D&A For EBITDA | 66.85 | 28.57 | 12 | 330.18 | 13.91 |
EBIT | 535.19 | 231.79 | 143.52 | 162.76 | 125.44 |
EBIT Margin | 25.08% | 17.97% | 12.56% | 16.19% | 14.31% |
Effective Tax Rate | 17.93% | 22.98% | 16.64% | 18.03% | 22.89% |